ArticleEmerging microbes & infections2026
Effectiveness of DTaP-IPV//PRP-T vaccine against pertussis among infants and toddlers in Zhejiang, China: a retrospective cohort study.
Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative analysis of adverse events following immunization with DTaP vaccine in children before and after immunization schedule adjustment.Human vaccines & immunotherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pertussis poses a significant risk, especially to infants. Although the pentavalent vaccine DTaP-IPV//PRP-T was introduced in China in 2010, real-world data on vaccine effectiveness (VE) in the country are limited. We conducted a retrospective cohort study using data from the Zhejiang Provincial Immunization Information System (ZIIS) and the National Notifiable Disease Surveillance System (NNDSS) to evaluate VE against pertussis between 2017 and 2019. Infants born between 1 January 2017 and 31 May 2019 were included. A multivariate Poisson regression was performed to estimate the effectiveness of different vaccine doses of DTaP-IPV//PRP-T against pertussis. Overall, 1,309,759, 1,215,924, 373,852 and 47,228 participants were enrolled in the 1-, 2-, 3- and 4-dose cohorts, respectively. During follow-up, 185 (14 per 100,000), 72 (6 per 100,000), and 49 (13 per 100,000), and 3 (6 per 100,000) pertussis cases were identified in each cohort, respectively. The adjusted VE of the primary three-dose regimen was 90.8% (95% CI, 79.5%-96.3%) in children aged 4.5-19.5 months, 59.8% (95% CI, 26.5%-80.4%) for the one-dose regimen in children aged 2.5-5.5 months, and 89.0% (95% CI, 69.3%-97.4%) for the two-dose regimen in children aged 3.5-6.5 months. These findings provide robust evidence that the DTaP-IPV//PRP-T vaccine is highly effective against pertussis in infants and toddlers within the Zhejiang setting. Ensuring timely administration and completion of the primary series is paramount for effective pertussis control in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.